4
Participants
Start Date
December 31, 2006
Primary Completion Date
February 28, 2007
Study Completion Date
February 28, 2007
alpha-1-Proteinase Inhibitor
Alpha-1-Proteinase Inhibitor was delivered I.V. A patient weighing 150 pounds was infused with approximately ½ cup containing 8.4 grams of alpha-1-Proteinase Inhibitor. Patients were admitted to hospital for infusion. The I.V. infusion was approximately 1 teaspoon/minute. Patients received weekly infusions of alpha-1-Proteinase Inhibitor for 8-12 weeks. At the time of infusion, 40ml (3 Tablespoons) of blood was collected (IRB approval #R04-003). The blood sample was used to monitor viral load, CD4 cell numbers, and alpha-1-Proteinase Inhibitor.
Cabrini Medical Center, New York
Collaborators (1)
CSL Behring
INDUSTRY
Institute for Human Genetics and Biochemistry
OTHER